Innovative cancer therapies can provide a new hope
Inhibiting T-cells in non-small-cell lung cancer: A study of a drug trial to improve NK-cell therapy
“The number of NK companies has just exploded,” says Todd Fehniger, an oncologist at Washington University School of Medicine in St. Louis, Missouri. As researchers test their ideas in early clinical trials, the field is anxious to see which approach, if any, will give people long-lasting results. A regulatory approval will spark a torrent of interest, which is why the field is still at this moment in time.
Others are taking advantage of known activating and inhibitory receptors to bolster existing NK cells. The company is testing a checkpoint blocker in a trial as a treatment for non-small-cell lung cancer. The drug causes both parts of the immune response because it blocks an inhibitoryreceptor found on NK cells and some T cells.
Some laboratories across the world are giving a steady stream of encouraging results. Several of these treatment approaches enlist the immune system in innovative ways. Some researchers are starting to find success with in situ vaccines, which create an immune response to a person’s tumours, after many years trying to develop therapeutic cancer vaccines. Others weaponize natural killer cells, which are less harmful than T-cell therapies. Guided missiles carrying conventional chemotherapy drugs directly into cancer cells are using other immune components.
For Bachanova, the work and the wait are well worth it on the basis of the remissions she has seen over the years that avoid the intense side effects common with T-cell therapies. “The patients feel good,” she says. “You witness that And it’s powerful.
Romee started a programme at Dana-Farber. He and his colleagues are trying to develop memory-like cells that can fight cancer with CARs.
The study also revealed important variables about the cell source that affected NK-cell activity. People who experienced the best outcomes received cells from their blood that were frozen within a matter of hours and did not have nucleated red blood cells. The one-year survival rate for those who received their cells from a certain cord-blood unit was over 70%. When the cord blood did not meet these standards, it was just 5%. She now uses only optimal cord blood after all of her protocols were changed when they came up with this.
CAR-T therapy requires the extraction of an individual’s own T cells and a two-to-four week wait for the cells to be engineered. One-third of recipients develop a cytokine release syndrome, which occurs when the cells are injected back into individuals, in which a rush of inflammatory molecule causes a patient to get sick and may require hospitalization. About one-quarter also develop neurotoxicity, which can be life-threatening3. All of this makes the price of therapy high — around US$400,000 — and limits it to people who are able to withstand the side effects.
As part of a study published in January, 37 people who had been through various failed treatments for blood cancer received infusions of genetically enhanced immune cells that researchers hoped would clear their disease1. T cells have been approved for therapies more than one time. But the source of the cells was.
Cancer kills approximately ten million people each year. According to one study, this disease, in all its many forms, will cost the world a whopping 25 trillion international dollars — an artificial currency used to compare economies — over the next 30 years (S. Chen et al. JAMA Oncol. 9, 465–472; 2023). More than 50 years after the US declaration of a war on cancer, many hoped that the disease would be closer to defeat than these statistics suggest. Many people diagnosed with cancer today contend with the dismal side effects of radiation, surgery and therapy, often with uncertain outcomes. New treatments for cancer will change the course of the disease.
The combination of therapy anddiagnostics is scoring very impressive results. To identify and locate cancer, radioactive particles have to be sent to the body, followed by a different class of emitters that can kill the cancer cells. Artificial intelligence can be used to determine which therapy is best for an individual. With new treatments emerging from labs so rapidly, it might be time to rethink the clinical-trial system lest people be deprived of the most effective treatments available.
We are pleased to acknowledge grant funding from MSD and the financial support of Pfizer in producing this Outlook. As always, Nature retains sole responsibility for all editorial content.
AstraZeneca is testing a checkpoint blocker in a late-stage clinical trial as a treatment for non-small-cell lung cancer. The drug causes both parts of the immune response because it blocks an inhibitoryreceptor found on NK cell and some T cells, researchers said. In a study of 37 people with blood cancer, researchers found that those who received their cells from a cord-blood unit survived over 70%.